AU2020235823A1 - Method for treating female non-smokers with non-small cell lung cancer - Google Patents

Method for treating female non-smokers with non-small cell lung cancer Download PDF

Info

Publication number
AU2020235823A1
AU2020235823A1 AU2020235823A AU2020235823A AU2020235823A1 AU 2020235823 A1 AU2020235823 A1 AU 2020235823A1 AU 2020235823 A AU2020235823 A AU 2020235823A AU 2020235823 A AU2020235823 A AU 2020235823A AU 2020235823 A1 AU2020235823 A1 AU 2020235823A1
Authority
AU
Australia
Prior art keywords
lung cancer
small cell
cell lung
patient
dithio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020235823A
Other languages
English (en)
Inventor
Arun ASAITHAMBI
Aditya KULKAMI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lantern Pharma Inc
Original Assignee
Lantern Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantern Pharma Inc filed Critical Lantern Pharma Inc
Publication of AU2020235823A1 publication Critical patent/AU2020235823A1/en
Priority to AU2025267367A priority Critical patent/AU2025267367A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
AU2020235823A 2019-03-08 2020-03-08 Method for treating female non-smokers with non-small cell lung cancer Abandoned AU2020235823A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025267367A AU2025267367A1 (en) 2019-03-08 2025-11-12 Method for Treating Female Non-Smokers with Non-Small Cell Lung Cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962815762P 2019-03-08 2019-03-08
US62/815,762 2019-03-08
PCT/US2020/021615 WO2020185640A1 (en) 2019-03-08 2020-03-08 Method for treating female non-smokers with non-small cell lung cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025267367A Division AU2025267367A1 (en) 2019-03-08 2025-11-12 Method for Treating Female Non-Smokers with Non-Small Cell Lung Cancer

Publications (1)

Publication Number Publication Date
AU2020235823A1 true AU2020235823A1 (en) 2021-11-04

Family

ID=72427123

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020235823A Abandoned AU2020235823A1 (en) 2019-03-08 2020-03-08 Method for treating female non-smokers with non-small cell lung cancer
AU2025267367A Pending AU2025267367A1 (en) 2019-03-08 2025-11-12 Method for Treating Female Non-Smokers with Non-Small Cell Lung Cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025267367A Pending AU2025267367A1 (en) 2019-03-08 2025-11-12 Method for Treating Female Non-Smokers with Non-Small Cell Lung Cancer

Country Status (11)

Country Link
US (1) US20220168258A1 (https=)
EP (1) EP3935043A4 (https=)
JP (2) JP2022525040A (https=)
KR (1) KR20220047208A (https=)
CN (2) CN113906010A (https=)
AU (2) AU2020235823A1 (https=)
BR (1) BR112021017716A2 (https=)
CA (1) CA3132827A1 (https=)
MX (1) MX2021010745A (https=)
SG (1) SG11202109705YA (https=)
WO (1) WO2020185640A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008352597B2 (en) * 2008-03-14 2012-03-08 Bionumerik Pharmaceuticals, Inc. Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
JP5667886B2 (ja) * 2008-03-14 2015-02-12 バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド 癌患者の生存時間を増大させるための組成物及び化合物の使用方法
CA2717915A1 (en) * 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods and compositions
US20170007561A1 (en) * 2014-08-08 2017-01-12 Bionumerik Pharmaceuticals, Inc. Contemporaneous, heterogeneously-oriented, multi-targeted therapeutic modification and/or modulation of disease by administration of sulfur-containing, amino acid-specific small molecules

Also Published As

Publication number Publication date
JP2022525040A (ja) 2022-05-11
EP3935043A4 (en) 2023-01-11
JP2025081338A (ja) 2025-05-27
BR112021017716A2 (pt) 2021-11-16
MX2021010745A (es) 2021-12-15
US20220168258A1 (en) 2022-06-02
EP3935043A1 (en) 2022-01-12
WO2020185640A1 (en) 2020-09-17
AU2025267367A1 (en) 2025-12-04
KR20220047208A (ko) 2022-04-15
CN120078760A (zh) 2025-06-03
SG11202109705YA (en) 2021-10-28
CA3132827A1 (en) 2020-09-17
CN113906010A (zh) 2022-01-07

Similar Documents

Publication Publication Date Title
Monnet et al. Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC)
Petrioli et al. Comparison between a cisplatin‐containing regimen and a carboplatin‐containing regimen for recurrent or metastatic bladder cancer patients: A randomized phase II study
WO2021089005A1 (zh) 一种fgfr抑制剂的用途
CN117377476B (zh) 治疗与化学疗法诱发的周围神经病变相关的疼痛
EP4537832A1 (en) Method for treating cancer patient with akr1c3 enzyme-activated prodrug
CN111184863B (zh) 酪氨酸激酶抑制剂、cdk4/6抑制剂、serd联合在制备治疗肿瘤的药物中的用途
WO1997027848A1 (en) SENSITIZATION OF HER2/neu OVER-EXPRESSING CANCER CELLS TO CHEMOTHERAPEUTIC DRUGS
CA3134156C (en) Chiauranib for treatment of small cell lung cancer
US20220168258A1 (en) Method for treating female non-smokers with non-small cell lung cancer
CN111249465A (zh) Topk作为宫颈癌顺铂耐药治疗靶点的应用
US20210379095A1 (en) Methods and Combination Therapy to Treat Biliary Tract Cancer
Tanaka et al. Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003)
CN110787173A (zh) 化合物在制备治疗多药耐药性癌症的药物的应用
Gent et al. An overview of chemotherapy-induced peripheral sensory neuropathy, focusing on oxaliplatin
WO2025137692A1 (en) Combination of dimesna and pemetrexed to treat non-small cell lung cancer (nsclc)
CN111718328A (zh) 4-甲基-1h-二芳基吡唑类衍生物在制备抗肿瘤药物中的用途
US20230172872A1 (en) Use of an rxr agonist and taxanes in treating her2+ cancers
JP2013510126A (ja) コリン含有医薬組成物
CN106038571A (zh) 一种含小分子靶向药物吉非替尼的药物组合物及其在制备抗肿瘤药物中的应用
TW202339753A (zh) 用於與抗癌藥物共同投與之包含酞嗪酮衍生物之醫藥組合物
Yang et al. JAB-2485: a potent, highly selective small-molecule Aurora Kinase A inhibitor that targets cell division
Lorusso et al. Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial
WO2011066545A1 (en) Treatment of human osteosarcoma

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted